President of Health and Biosciences
Inspired by nature and distinguished by creativity and innovation, IFF’s Health and Biosciences business unit partners with customers to deliver sustainable, high-performance solutions. The portfolio includes probiotics, cultures, and enzymes solutions that support health, food, and home applications. Before joining IFF, Leticia served as president of Precision Fermentation and ADM Ventures at ADM as well as a member of the company’s Executive Council. In this role, she led ADM’s global innovation strategy and execution, including oversight of its venture investment portfolio, business incubation efforts and partnerships. Previously, Leticia served as president of Global Foods, where she oversaw food ingredients, savory, sweet goods and dairy businesses and managed a high-growth global P&L.


An international leader, Leticia brings deep market insight shaped by living in Europe, Brazil and the U.S., where she also led impactful, diverse teams.
Before joining IFF, Leticia served as president of Precision Fermentation and ADM Ventures at ADM as well as a member of the company’s Executive Council. In this role, she led ADM’s global innovation strategy and execution, including oversight of its venture investment portfolio, business incubation efforts and partnerships. Previously, Leticia served as president of Global Foods, where she oversaw food ingredients, savory, sweet goods and dairy businesses and managed a high-growth global P&L.
An international leader, Leticia brings deep market insight shaped by living in Europe, Brazil and the U.S., where she also led impactful, diverse teams.
Appointed President, Health & Biosciences (H&B) at IFF effective March 1, 2025, succeeding Simon Herriott; brings extensive P&L and innovation leadership across ADM, Bayer, and Monsanto.
Leads IFF’s biotechnology platform (probiotics, cultures, enzymes) focused on sustainable, high‑performance solutions for health, food, home care—aligned with IFF’s 2025 operating model.
Guided strategic partnerships that advance H&B innovation, including IFF’s 2025 collaboration with BASF to accelerate Designed Enzymatic Biomaterials™ for next‑gen enzyme and polymer solutions in home & personal care.







